SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

Inclusion Criteria: * Patient aged 18 years or over * Patient who have been informed of the objectives and the conditions of the study and who did not object to its participation * Patient diagnosed with one chronic inflammatory rheumatological (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) or chronic inflammatory bowel (Crohn's disease, ulcerative colitis) diseases * Patient for whom the investigator has decided, with patient's agreement and prior to inclusion: * Or to initiate adalimumab by prescribing a biosimilar (Adalimumab FK) * Either to replace Humira® with a biosimilar (AdalimumabFK) Exclusion Criteria: * Patient enrolled in an interventional therapeutic trial at the time of inclusion * Patient refusing or unable to comply with the study follow-up procedures (patient not contactable by telephone, unable to complete the self-administered questionnaire, or having poor French language skills, etc.)